The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00221182
(slow recruitment of the study subjects)
: September 22, 2005
Last Update Posted
: June 22, 2011
Foundation for Biomedical Research and Innovation
Institute of Biomedical Research and Innovation, Kobe, Hyogo, Japan
The purpose of this study is to determine if stem cell therapy with your own cells (autologous cells) delivered with a catheter to regions of the heart with poor blood flow will be safe and if it will relieve your chest pain, increase the blood flow, and/or improve the cardiac contractility (function) by regenerating blood vessels in your heart.
Chronic myocardial ischemia (MI) is a progressive disease, which arises as a result of atherosclerosis in coronary arteries. Prognosis of chronic MI is poor, and no effective treatments have been established in patients who are not eligible for the traditional revascularization therapies such as angioplasty and bypass procedures due to the inappropriate anatomy of the coronary arteries or frequent reocclusion following revascularization. Therefore, it is necessary to establish novel revascularization treatment to improve prognosis of the no-option patients. We will study the safety and clinical efficiency of vascular regeneration by means of transplantation of autologous peripheral blood endothelial progenitor cells (CD34 positive cells) in patients with severe chronic coronary artery disease (CAD) who are not eligible for traditional revascularization treatments. The primary endpoint is the severity of myocardial ischemia identified by sestamibi SPECT stress myocardial scintigraphy and the evaluation of adverse effect rates, while the secondary endpoints are evaluation of CCSAS and NYHA classification, regional myocardial blood flow as revealed by PET scan, and various left ventricular function indices.
Phase I / II Clinical Trial Regarding Vascular Regeneration Therapy by Transplantation of Autologous Peripheral Blood Endothelial Progenitor Cells (CD34+ Cells) in No-Option Patients With Chronic Myocardial Ischemia
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
-Chronic severe CAD patients fulfilling all the following criteria are considered suitable for inclusion in the study.
At least 6 months since last episode of myocardial infarction or at least 3 months since initial anginal episode.
Patients fulfilling either of the following criteria based on the extent of CAD by coronary angiography and LVEF by echocardiography.
Patients with single vessel CAD and LVEF < 50%
Patients with multivessel CAD
Reversible myocardial ischemia as revealed by sestamibi SPECT stress myocardial scintigraphy.
Patients for whom angioplasty and bypass are not indicated because of anatomical or procedural reasons or frequent reocclusion/restenosis following traditional revascularization.
Age is between 20 and 80 (at time of consent).
Exercise tolerance time (ETT) duration ≥ 3 minutes and < 13 minutes on a modified Bruce protocol on 2 consecutive tests (> 24 hours but < 2 weeks apart), with the difference between the 2 exercise times within 25% of their mean (Patients should not be informed of exercise restrictions required for entry into the study).
Patients who can give informed consent themselves in writing.
Any one of the following exclusion criteria is sufficient to disqualify a patient from the study.
Sustained ventricular tachycardia in a 24-hour ECG.
Chronic atrial fibrillation.
Less than 6 months since last episode of cerebral infarction.
Less than 6 months since last coronary angioplasty or less than 3 months since last bypass surgery.
Patients with unstable angina, with a treatment rating of 3 in the Braunwald system (refer to 5.4.), but a severity of III and a clinical rating of B or C.
Presence of left ventricular thrombus by echocardiography
Patients with a malignant tumor*.
Patients with diabetic proliferating retinopathy** (new Fukuda classification BI to BV).
Patients with chronic rheumatoid arthritis.
Patients with a history of severe allergic reactions or side effects to G-CSF preparations or apheresis.
Patients with hematological disease (leukemia, myeloproliferative disease, or myelodysplastic syndromes).
Patients currently suffering from or having a history of interstitial pneumonitis.
Patients for whom cranial MRA reveals cerebral aneurysm.
Patients for whom abdominal CT or ultrasonography reveals splenomegaly.
Patients with cirrhosis of the liver.
Patients who cannot discontinue Warfarin.
Leukocytes less than 4,000/µL or exceeding 10,000/µL.
Platelets less than 100,000/µL.
Hemoglobin less than 10 g/dL.
AST (GOT) exceeding 100 IU/L or ALT (GPT) exceeding 100 IU/L.
Patients for whom it is impossible to perform both cardiac MRI and left ventriculography (LVG) (see 9.2.4 for cardiac MRI details and 9.2.9 for LVG details).
Patients with gate disturbance for reasons other than CAD (such as critical limb ischemia, sciatic neuralgia, or vasculitis), making exercise tolerance evaluation on a treadmill with stress ECG difficult.
Pregnant or nursing patients, those who may be pregnant, or those who plan on becoming pregnant before the end of the study period.
Any other reason that the Clinical Supervisors or Clinical Researchers may have for considering a case unsuitable for the study.